DE60103171D1 - Verfahren und verbindungen zur behandlung proliferativer erkrankungen - Google Patents

Verfahren und verbindungen zur behandlung proliferativer erkrankungen

Info

Publication number
DE60103171D1
DE60103171D1 DE60103171T DE60103171T DE60103171D1 DE 60103171 D1 DE60103171 D1 DE 60103171D1 DE 60103171 T DE60103171 T DE 60103171T DE 60103171 T DE60103171 T DE 60103171T DE 60103171 D1 DE60103171 D1 DE 60103171D1
Authority
DE
Germany
Prior art keywords
links
proliferative diseases
treating proliferative
formula
indolocarbazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60103171T
Other languages
English (en)
Other versions
DE60103171T2 (de
Inventor
Albert Engler
Wayne Furness
Sushant Malhotra
Lyle Briggs
Burns Brooks
Keyes Clawson
Concepcion Sanchez-Martinez
Faming Zhang
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60103171D1 publication Critical patent/DE60103171D1/de
Application granted granted Critical
Publication of DE60103171T2 publication Critical patent/DE60103171T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60103171T 2000-09-29 2001-09-24 Verfahren und verbindungen zur behandlung proliferativer erkrankungen Expired - Fee Related DE60103171T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23661600P 2000-09-29 2000-09-29
US236616P 2000-09-29
PCT/US2001/027728 WO2002028861A2 (en) 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases

Publications (2)

Publication Number Publication Date
DE60103171D1 true DE60103171D1 (de) 2004-06-09
DE60103171T2 DE60103171T2 (de) 2004-11-11

Family

ID=22890242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103171T Expired - Fee Related DE60103171T2 (de) 2000-09-29 2001-09-24 Verfahren und verbindungen zur behandlung proliferativer erkrankungen

Country Status (10)

Country Link
US (1) US7109229B2 (de)
EP (1) EP1325011B1 (de)
AT (1) ATE266031T1 (de)
AU (1) AU2001292579A1 (de)
DE (1) DE60103171T2 (de)
DK (1) DK1325011T3 (de)
ES (1) ES2220811T3 (de)
PT (1) PT1325011E (de)
TR (1) TR200401316T4 (de)
WO (1) WO2002028861A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
EP2102207B1 (de) 2006-12-07 2010-06-02 F.Hoffmann-La Roche Ag Spiropiperidinderivate als antagonisten des via-rezeptors
AU2007338115A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
MX2011005055A (es) 2008-11-19 2011-05-31 Cephalon Inc Nuevas formas de un compuesto de indazolo [5,4-a]pirrolo[3,4-c]car bazol.
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
MX2012013304A (es) * 2010-05-18 2013-04-03 Cephalon France Metodo para purificar un derivado de pirrolocarbazol fusionado.
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
JP2013545758A (ja) 2010-11-17 2013-12-26 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
JP6337083B2 (ja) 2013-03-15 2018-06-06 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (de) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217964A1 (de) 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
TR200401316T4 (tr) 2004-07-21
AU2001292579A1 (en) 2002-04-15
ES2220811T3 (es) 2004-12-16
PT1325011E (pt) 2004-09-30
DK1325011T3 (da) 2004-08-16
ATE266031T1 (de) 2004-05-15
WO2002028861A8 (en) 2003-11-20
DE60103171T2 (de) 2004-11-11
WO2002028861A2 (en) 2002-04-11
EP1325011B1 (de) 2004-05-06
EP1325011A2 (de) 2003-07-09
WO2002028861A3 (en) 2002-08-01
US7109229B2 (en) 2006-09-19
US20040048915A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DE60103171D1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
BR0207811A (pt) Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
DE69940951D1 (de) Nd wachstumshemmende mittel
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE549023T1 (de) Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
NO20063331L (no) Nikotinacetylcholinreseptorligander
ATE281455T1 (de) Oxindolderivate
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
SG149052A1 (en) Nicotinic acetylcholine receptor ligands
ATE293107T1 (de) Luminacine analoge und deren verwendung
DE602004025849D1 (de) Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee